Employees: 147
Size Aquestive Therapeutics (AQST) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $475M, the 2708th largest of 3,085 United States companies the cockpit tracks. Shares closed at $3.78 on 18 Nov 2026.
Performance Over six months the shares fell 9.3%, against -14.7% for the median peer and -2.2% for the United States market (cap-weighted) — 10th highest of 20 in its peer set.
Growth Revenue grew 12.5% over the last twelve months (peer median +9.4%); the operating margin is -114.1% (peer median 10.7%).
Valuation It trades at 10.9× enterprise value to sales against a peer median of 4.6× (4th most expensive of 19).
Short interest Short interest is 23.3% of the free float (30 Oct 2026).
Next results Next results expected around 9 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $48.8M | $44.5M | $57.6M | $50.6M | $47.7M |
| Revenue growth | — | -23% | +14% | +6% | — |
| Gross profit | $31.9M | $27.4M | $39.7M | $30.0M | $27.8M |
| EBITDA | -$55.2M | -$69.1M | -$30.1M | -$13.5M | -$39.7M |
| Net income | -$79.3M | -$83.8M | -$44.1M | -$7.87M | -$54.4M |
| Free cash flow | -$40.7M | -$53.0M | -$35.9M | -$7.38M | -$10.8M |
| Capital expenditure | $933,000 | $562,000 | $159,000 | $995,000 | $2.52M |
| Total debt | $150M | $131M | $122M | $98.8M | $123M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | AQST | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -6.7% | -2.6% | 8th lowest of 21 |
| 6-month return | -9.3% | -14.7% | 10th highest of 20 |
| Distance from 52-week high | -43.9% | -38.3% | 8th lowest of 21 |
| Revenue growth (TTM) | +12.5% | +9.4% | 10th highest of 20 |
| Operating margin | -114.1% | 10.7% | 3rd lowest of 19 |
| EV / Sales | 10.9× | 4.6× | 4th most expensive of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Aquestive Therapeutics AQST | United States | $475M | -9% | +13% | -114% | 10.9× | n/a | n/a |
| SMS Pharmaceuticals SMSPHARMA.NS | India | $477M | +16% | +13% | 16% | 4.9× | n/a | n/a |
| YungShin Global 3705.TW | Taiwan | $472M | +5% | -5% | 15% | 2.0× | -3.8% | +0.7% |
| Shanghai Fudan Forward S&T 600624.SS | China | $478M | 0% | -14% | -34% | 6.4× | n/a | n/a |
| ChengDa PharmaCeuticals 301201.SZ | China | $472M | -47% | +27% | -9% | 4.8× | n/a | n/a |
| Hansa Biopharma HNSA.ST | Sweden | $479M | +39% | +69% | -190% | 14.9× | -4.7% | +105.3% |
| REGENXBIO RGNX | United States | $480M | +22% | -5% | -120% | 3.1× | n/a | n/a |
| Shanghai MicuRx Pharmaceutical 688373.SS | China | $481M | -8% | +23% | -61% | 19.0× | n/a | n/a |
| Handa Pharmaceuticals 6620.TWO | Taiwan | $469M | +45% | -16% | 30% | 16.6× | 24.8% | +126.7% |
| Evolus EOLS | United States | $468M | +7% | +14% | -5% | 1.8× | n/a | n/a |
| Zhejiang Yatai Pharmaceutical 002370.SZ | China | $468M | -32% | -4% | -11% | 8.8× | n/a | n/a |
| Capricor Therapeutics CAPR | United States | $467M | -70% | -100% | n/a | n/a | n/a | n/a |
| Kwality Pharmaceuticals KPL.NS | India | $467M | +110% | +48% | 22% | 7.2× | n/a | n/a |
| Hainan Shuangcheng Pharmaceuticals 002693.SZ | China | $465M | -28% | +40% | 13% | 10.8× | 44.1% | +1.0% |
| Hefei Lifeon Pharmaceutical 003020.SZ | China | $486M | -21% | -1% | 10% | 2.0× | n/a | n/a |
| BlossomHill Therapeutics BLSM | United States | $464M | n/a | n/a | n/a | n/a | n/a | n/a |
| Nanjing Hicin Pharmaceutical 300584.SZ | China | $487M | -29% | +32% | 17% | 4.3× | 3.3% | -1.1% |
| Newland Pharmaceutical 301277.SZ | China | $488M | -22% | +9% | 11% | 3.5× | 8.9% | +9.1% |
| Tong Ren Tang Technologies 1666.HK | Hong Kong | $491M | -19% | -14% | 12% | 0.6× | -17.2% | +6.3% |
| Assembly Biosciences ASMB | United States | $458M | -15% | +80% | -32% | 2.2× | n/a | n/a |
| Shandong Wohua Pharmaceutical 002107.SZ | China | $493M | -20% | -4% | 18% | 3.7× | 5.9% | -4.1% |